



# Swiss Biotech Day 2026

Media conference

May 4, 2026, Congress Center Basel



# Swiss Biotech Report 2026

Frederik Schmachtenberg, Michael Altorfer

May 4, 2026

# Steering Committee Swiss Biotech Report 2026



**Michael Altorfer**



**Hans-Peter Meyer**



**Frederik Schmachtenberg**



**Christian Moser Nikles**



**Florian Fisch**



**Jörg Schläpfer**



**Jan Lucht**



**Sirpa Tsimal**



# Strong performance - records in revenues and investments in privately funded companies

- Total revenues reach record CHF 7.5 billion
- Total funding increased by 2.1% to CHF 2.6 billion
- Notable shift in investment in privately funded companies to record CHF 1.15 billion – up 38% from 2024, reaching 45% of total funding
- Windward Bio (CHF 186 million) and GlycoEra (CHF 104 million) led the way in private rounds
- BioVersys completed Europe's largest IPO, while an increasing number of companies leveraged collaborations for financing
- Slightly reduced number of product approvals in the US, Europe and Switzerland, but uptick in other key markets, including China and Canada
- R&D investment dipped slightly to CHF 2.5 billion, but employment reached record levels
- Switzerland top of the Global Innovation Index for 15<sup>th</sup> consecutive year
- Eureka Global Innovation Summit follows the Swiss Biotech Day






## The year in figures



The data in the presented tables is based on information that was available up until March 31, 2026. At this time, some of the companies had not yet disclosed their financial figures for 2025. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e., Q3 or Q4 2025).

# Capital investments in Swiss biotech companies 2016-2025

## Private and public Swiss biotech companies



Source: EY (Capital investments include convertible bonds)

# Swiss biotech companies raised a total of CHF 2.6 bn in 2025

## Largest public and private financing rounds

### 2025 public financing rounds

PUBLIC COMPANIES	CHF MILLION
Moonlake Immunotherapeutics	490
Oculis	274
Idorsia	216
ADC Therapeutics	129
Bioversys	80
<b>Total</b>	<b>1'189</b>


### 2025 private financing rounds

PRIVATE COMPANIES	CHF MILLION
Windward Bio	186
GlycoEra	104
Orbis Medicines	84
Nuclidium	79
Rhygaze	78
<b>Total</b>	<b>531</b>

Source: Annual reports, website information, EY, Swiss Biotech Association


# Biotech financing categories in Switzerland 2016-2025

## History of financing categories in Switzerland



Source: Annual reports, website information, EY, Swiss Biotech Association


# Private & public Swiss regional financing 2023-2025



Source: Annual reports, website information, EY, Swiss Biotech Association

# Revenues, R&D expenses, profit/loss, liquidity 2023-2025

## Total Swiss biotech companies




Source: Annual reports, website information, EY, Swiss Biotech Association

Note: The 2025 data in above tables is based on information that was available up until March 31, 2026. At this time, some of the companies had not yet disclosed their financial figures for 2025. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e., Q3 or Q4 2025).

# Revenues, R&D expenses, profit/loss, liquidity 2023-2025

## Public Swiss biotech companies




Source: Annual reports, website information, EY

Note: The 2025 data in above tables is based on information that was available up until March 31, 2026. At this time, some of the companies had not yet disclosed their financial figures for 2025. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e., Q3 or Q4 2025).


# Revenues, R&D expenses, profit/loss, liquidity 2023-2025

## Private Swiss biotech companies




Source: Swiss Biotech Association, EY, (incl. estimates and extrapolations based on prior year figures)

# Number of biotech companies in Switzerland 2016-2025



Source: Swiss Biotech Association, website information and EY


# Employees in Swiss R&D biotech companies 2023-2025



Source: Annual reports, website information, EY, Swiss Biotech Association

# Life sciences exports rise to CHF 118.4 billion

Immunological subsector accounts for CHF 57.4 billion or 20% of Swiss exports



scienceindustries/Federal Customs Administration 2026, Swiss IMPEX database

The life sciences sector has been the strongest contributor to Swiss exports every year since 2013



# The Swiss Biotech Report 2026

## Talent and Tenacity

# A remarkable capacity to attract global talent

Switzerland can shape the future of biotech



*“Switzerland’s biotech ecosystem stands today at a defining moment. With a strong base of jobs across the broader life sciences sector, sustained growth, and a remarkable capacity to attract global talent, it is clear that our country has built one of the most dynamic and competitive environments for innovation in the world.”*

**Andre Hoffmann**

Vice Chair Roche Holding &  
Co-Chair World Economic Forum

# An outstanding record of success

Consistently leading world talent rankings

## A: INSEAD GLOBAL TALENT COMPETITIVENESS INDEX




## B: IMD WORLD TALENT RANKING



# A multinational talent pool, global in outlook

Deployed across the whole sector – industry, academia, healthcare system & government



**A few examples of Swiss  
science & business talent  
development and impact**



# Fostering young talent



*“The SNSF funding schemes enable young scientists to pursue their own ideas, deepen their expertise and prepare themselves for the fierce international competition in academia or the private sector.”*

*“Currently SNSF supports over 6'600 doctoral students and around 4'200 postdocs through its career schemes, projects and programs. 64% of postdocs who left academia joined the private sector.”*

**Florian Fisch**

Swiss National Science Foundation

# Creating standout inventors




*“Challenging the status quo and thinking how can things be further improved is what drives us. We are always attracted to the next challenge, not doing a “me-too” kind of thing, but going a step further to develop first-in-class or best-in-class approaches by addressing key questions, even if they appear very difficult in the beginning.”*

*“We have always been surrounded by very good teams, which enabled us to collaborate with exceptionally productive and expert colleagues.”*

**Christian Klein and Pablo Umaña**  
Swiss-based scientists

# Cultivating tomorrow's biotech pioneers today




*“Biotechnology - drawing on the versatility, precision, and efficiency of biological systems - offers powerful tools to emulate nature’s principles across a wide range of industries, far beyond pharmaceuticals and advanced therapeutics. Switzerland’s success in attracting the talent capable of driving a transition from unsustainable to sustainable manufacturing will help to achieve its goal of a circular economy.”*

**Hans-Peter Meyer**  
SATW



# World-class talent pool facilitates global collaboration



*“Few countries can match Switzerland’s breadth and depth of talent across the biotech value chain in therapeutic modalities, including small molecules and biologics, cell and gene therapies, RNA, and digital health.”*

*“Switzerland’s future depends on an ecosystem that invests in talent, rewards determination, supports entrepreneurial freedom, and thrives through international collaboration. Its competitive edge lies in its people: focused on developing solutions for global challenges and building international alliances.”*

**Michael Altorfer & Natasha Konstantinova**  
Swiss Biotech Association

# Global manufacturing hub built on talent



*“Switzerland is the chosen location of a large number of world-class biomanufacturing facilities. In addition to its strong focus on therapeutics and drug products, Switzerland’s biomanufacturing sector extends beyond the pharmaceutical industry.”*

*“Strong talent, innovation, collaboration, and long-term strategy are some of the factors that underpin Switzerland’s global impact.”*

**Jan Lucht**  
scienceindustries

# From discovery to commercial HQ, talent to meet all needs



*“What stands out to me about Switzerland is the depth and maturity of its commercial and executive talent. Leaders here gain exposure to complex launches, global market access, and multiple therapeutic areas, while also having the opportunity to grow their scope and impact without needing to move between regions - which is critical for long-term retention.”*

**Alexey Kutahov**  
Mirum Pharmaceuticals



*“A key enabler is Switzerland’s dual combination of vocational and academic talent. It allows Swiss manufacturing hubs to operate highly regulated, technology-intensive production sites, implement new platforms and modalities, and scale processes efficiently.”*

**Carl Deutsch**  
NBE Therapeutics

# Providing the talent to drive TechBio, Switzerland's next wave of innovation



*“Switzerland’s dual education system blends strong vocational training with elite academic pathways, spanning ETH Zurich, EPFL, the country’s ten universities, and eight universities of applied sciences, enabling lifelong mobility and global competitiveness.”*

*“This is helping to ensure Switzerland will have the talent needed to be impactful in TechBio, where biology, data, engineering, and digital tools converge to unlock new possibilities in health, sustainability, and industrial biotechnology.”*

**Samantha Paoletti & Gilles Weder**  
CSEM

# SWISS BIOTECH SUCCESS STORIES

Sponsors:



Supported by:

**WISSENSCHAFT.  
BEWEGEN**  
GEBERT RUF STIFTUNG | Basel-Stadt | TS Kommunikation

Organized by:





# SWISS BIOTECH SUCCESS STORIES

## Celebrating and honoring major achievements

- The Swiss Biotech Association annually awards individuals or organizations for outstanding contributions to the biotech industry
- Dedicated to scientists, pioneers, entrepreneurs, innovators and supporters who led the way, opened the horizon and prepared the ground for lasting achievements
- Swiss Biotech Success Stories accentuate past industry highlights and act as motivator for future achievements

# Success Stories Award winner 2026



**Patrick Aebischer**

Scientist, leader, entrepreneur

Founder of four biotech companies:



# SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring  
major achievements

# Swiss Biotech Day: Global Village

presented by Swiss Biotech Association, supported by S-GE and Innosuisse



In the Global Village, we aim to strengthen the bilateral relationships between the guest countries and Switzerland in the life science sector.

**International reception of the Global Village**, May 4, 6:00 pm, room San Francisco, top floor

**Global Village, plenary session**, May 4, 2:15 pm, room Osaka/Samarkand, top floor

**Marketplace reception**, May 5, 3:30 pm, room San Francisco, top floor

# Swiss Biotech Day: Global Village

11 new delegations attending this year



Africa



Baden-Württemberg



Chile



Emilia-Romagna



Flanders



Latvia



Lithuania



North Rhine-Westphalia



Portugal




Slovenia



UK

# Swiss Biotech Report 2026 – 2025 key figures at a glance



**Save the date!**

# SWISS BIOTECH DAY 2027

April 26–27, 2027 – Congress Center Basel

